HLA Protein Technologies Inc.
HLA Protein Technologies’ New NCI License Speeds TCR Immunotherapy and Oncology Discovery
OKLAHOMA CITY, Okla. — HLA Protein Technologies, Inc. (formerly Pure Protein, LLC), a global leader in soluble, natively folded HLA proteins and custom peptide binding services, announced a major step forward for TCR research. The Company has secured an internal use license from the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), covering advanced T-cell receptor (TCR) compositions and methods….
HLA Protein Technologies Debuts sHLA-G Monomer and Tetramer Portfolio for High-Fidelity Checkpoint Biology, Target Validation, and Assay Development
OKLAHOMA CITY, Okla. — HLA Protein Technologies, Inc. (formerly Pure Protein, LLC) today announced the commercial launch of its new soluble HLA-G (sHLA-G) product portfolio, marking an expansion of its next-generation HLA research tools. HLA-G is a non-classical MHC Class I molecule recognized as a key immune checkpoint regulator….
HLA Protein Technologies Announces Next-Gen HLA Product Lines and Strategic Investment
OKLAHOMA CITY, Okla. — HLA Protein Technologies, Inc. (formerly Pure Protein, LLC) reports that its new manufacturing expansion is positioned to support the Company’s growth. A new product line launch, a strategic investment led by a private investor group; and a corporate rebrand to HLA Protein Technologies, reflects the company’s expanded focus on advanced immunology and oncology research tools….